SCHEMBL23249152

SCHEMBL23249152

CCOC(=O)C(CC(C)C)n1cc(CN(C)C)c(C(F)(F)F)cc1=O

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.32
KDR P35968 1/20 0.32
SLC5A1 P13866 1/20 0.32
SLC5A2 P31639 1/20 0.32
MAPT P10636 1/20 0.31
EPHX2 P34913 4/20 0.31
PPARG P37231 3/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
HTR2A P28223 1/20 0.31
NPSR1 Q6W5P4 1/20 0.30
CMA1 P23946 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
RAF1 P04049 1/20 0.30
BRAF P15056 1/20 0.30
BAZ2B Q9UIF8 1/20 0.30
BAZ2A Q9UIF9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29863760 0.97 POLQ (0.32) RETKDRSLC5A1SLC5A2MAPT
SCHEMBL31629452 0.90 F11 (0.33) RETKDREPHX2HTR2ACMA1
SCHEMBL21459374 0.89 HTR6 (0.32) SLC5A1SLC5A2MAPTEPHX2PPARG
SCHEMBL23250487 0.88 THRA (0.31) MAPTCMA1
SCHEMBL23249219 0.88 POLQ (0.34) SLC6A2SLC6A4SLC6A3
SCHEMBL29863674 0.87 POLQ (0.31)
SCHEMBL23249019 0.85 SLC5A1 (0.32) SLC5A1SLC5A2MAPTEPHX2PPARG
SCHEMBL23249545 0.82 PTPN2 (0.33) SLC5A1SLC5A2MAPTEPHX2MEN1
SCHEMBL23250246 0.81 MEN1 (0.31) MEN1KMT2A
SCHEMBL23249126 0.81 KDM4E (0.33) MAPTEPHX2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559525-A2 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 Morphic Therapeutic, Inc. (US) 2025-05-28 EP disclosed
EP-4045039-B1 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 MORPHIC THERAPEUTIC INC (US) 2025-04-23 EP disclosed
US-20240174632-A1 INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) MORPHIC THERAPEUTIC, INC. (US) 2024-05-30 US disclosed
CN-115087444-A Inhibition of human integrin alpha 4 β 7 莫菲克医疗股份有限公司 2022-09-20 CN disclosed
EP-4045039-A1 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 Morphic Therapeutic, Inc. (US) 2022-08-24 EP disclosed
US-11370773-B1 Inhibiting human integrin (alpha-4) (beta-7) MORPHIC THERAPEUTIC, INC. (US) 2022-06-28 US disclosed
US-11370773-B1 Inhibiting human integrin (alpha-4) (beta-7) MORPHIC THERAPEUTIC, INC. (US) 2022-06-28 US disclosed
WO-2021076902-A1 INHIBITING HUMAN INTEGRIN α 4 β 7 MORPHIC THERAPEUTIC, INC. (US) 2021-04-22 WO disclosed
WO-2021076890-A1 INHIBITING HUMAN INTEGRIN α4β7 MORPHIC THERAPEUTIC, INC. (US) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370773-B1 Inhibiting human integrin (alpha-4) (beta-7) ITGB7, ITGB4, ITGA4 RET 3644/4885KDR 850/4885SLC5A1 2423/4885
US-20240174632-A1 INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) ITGB7, ITGB4, ITGA4 RET 3644/4885KDR 850/4885SLC5A1 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.